Comparison of four distinct detection platforms using multiple ligand binding assay formats

Catherine I Soderstrom1, Franklin P Spriggs, Wei Song

  • 1Pfizer, Inc, 558 Eastern Point Road Groton, CT 06340, United States.

Summary

Comparing ligand binding assay (LBA) detection platforms reveals no single best option. Testing multiple platforms like colorimetric, chemiluminescence, TRF, and ECL is crucial for optimal biotherapeutic agent detection.

Related Concept Videos